Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guideline – Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Ann Oncol. 2023;34(4):358-376.
Hendriks L E, Kerr K, Menis J, et al. on behalf of the ESMO Guidelines Committee

  • This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing non-oncogene addicted mNSCLC.
  • The guideline covers diagnosis, staging, risk assessment, treatment and disease monitoring.
  • ESMO-MCBS scores are given to describe the levels of evidence for treatment choices.
  • ESCAT scores are given to describe the evidence level for genomic alterations as biomarkers for using targeted therapies.
  • Recommendations are based on available scientific data and the authors’ collective expert opinion.
  • In clinical practice, all recommendations provided need to be discussed with patients in a shared decision-making approach.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.